Topperke schreef op 8 mei 2017 09:17:
Hi Robbe,
Thank you for reaching out to us with your concerns and let me assure you that we are trying to improve our communication with our investors. I joined the company about three months ago and will be instrumental in making this happen. If you ever have questions, you can feel free to reach out to me directly.
Now, regarding your questions about our trading update:
Our total revenue for the first 4 months of 2017 was $19.4m and includes the buy-out transaction with Exact Sciences for a net amount of approx. $12m. Excluding this transaction, revenue from products and services of $7.4m increased compared to the same period last year (the revenue stated in last year’s trading update included a significant amount of royalty and milestone income).
We are confident that we will achieve our 2017 guidance of 55-75% product and service revenue growth and expect stronger growth in the remainder of the year. It’s still early in the year and the GSA contract will only start to make a significant contribution by the second half. We anticipate that product volume will increase once more veterans hospitals are set-up to order ConfirmMDx, new US payor contracts contribute to broader use and reimbursement, SelectMDx continues to gain traction in the US and the SelectMDx CE-marked IVD kit is rolled out in Europe.
Please note that interim trading updates are not mandatory and we volunteered to issue one and to include four months. The April numbers were available and we wanted to provide as recent an update as possible.
I hope this helps!
Kindest Regards,
Shalon